These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1348 related items for PubMed ID: 30472914

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
    Savarese G, Butler J, Lund LH, Bhatt DL, Anker SD.
    Cardiovasc Res; 2022 Jul 27; 118(10):2231-2252. PubMed ID: 34390570
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D, Javor E, Lucijanić T, Skelin M.
    Ann Med; 2017 Feb 27; 49(1):51-62. PubMed ID: 27535028
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME, Kosiborod M.
    Diabetes Obes Metab; 2019 Apr 27; 21 Suppl 2():19-23. PubMed ID: 31081589
    [Abstract] [Full Text] [Related]

  • 11. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F, Martins VM, Scheffel RS, da Silveira AD, Motta MT, Moriguchi EH, Santos RD, Stein R.
    Ann Pharmacother; 2021 Oct 27; 55(10):1267-1275. PubMed ID: 33401940
    [Abstract] [Full Text] [Related]

  • 12. Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021.
    Gonzalez J, Dave CV.
    BMC Cardiovasc Disord; 2024 May 30; 24(1):285. PubMed ID: 38816795
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
    Becher PM, Schrage B, Ferrannini G, Benson L, Butler J, Carrero JJ, Cosentino F, Dahlström U, Mellbin L, Rosano GMC, Sinagra G, Stolfo D, Lund LH, Savarese G.
    Eur J Heart Fail; 2021 Jun 30; 23(6):1012-1022. PubMed ID: 33599357
    [Abstract] [Full Text] [Related]

  • 15. Clinical pharmacology of SGLT-2 inhibitors in heart failure.
    Velliou M, Polyzogopoulou E, Ventoulis I, Parissis J.
    Expert Rev Clin Pharmacol; 2023 Feb 30; 16(2):149-160. PubMed ID: 36701817
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE, Ahuja T, Bridgeman MB.
    Ann Pharmacother; 2018 Dec 30; 52(12):1238-1249. PubMed ID: 29911393
    [Abstract] [Full Text] [Related]

  • 18. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS, Correa A, Contreras JP.
    Eur Heart J Cardiovasc Pharmacother; 2022 May 05; 8(3):311-321. PubMed ID: 34264341
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure.
    Ghosh RK, Ghosh GC, Gupta M, Bandyopadhyay D, Akhtar T, Deedwania P, Lavie CJ, Fonarow GC, Aneja A.
    Am J Cardiol; 2019 Dec 01; 124(11):1790-1796. PubMed ID: 31627834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.